Nextage Therapeutics (Israel) Performance
| MCTC Stock | ILA 81.00 1.90 2.29% |
On a scale of 0 to 100, Nextage Therapeutics holds a performance score of 6. The company secures a Beta (Market Risk) of 2.22, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nextage Therapeutics will likely underperform. Please check Nextage Therapeutics' maximum drawdown, potential upside, semi variance, as well as the relationship between the value at risk and downside variance , to make a quick decision on whether Nextage Therapeutics' current price movements will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Nextage Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Nextage Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 481 K | |
| Total Cashflows From Investing Activities | 13 K | |
| Discontinued Operations | -23 K |
Nextage |
Nextage Therapeutics Relative Risk vs. Return Landscape
If you would invest 6,990 in Nextage Therapeutics on August 26, 2024 and sell it today you would earn a total of 1,110 from holding Nextage Therapeutics or generate 15.88% return on investment over 90 days. Nextage Therapeutics is generating 0.4436% of daily returns and assumes 5.1989% volatility on return distribution over the 90 days horizon. Simply put, 46% of stocks are less volatile than Nextage, and 92% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Nextage Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nextage Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nextage Therapeutics, and traders can use it to determine the average amount a Nextage Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0853
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MCTC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.2 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Nextage Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nextage Therapeutics by adding it to a well-diversified portfolio.
Nextage Therapeutics Fundamentals Growth
Nextage Stock prices reflect investors' perceptions of the future prospects and financial health of Nextage Therapeutics, and Nextage Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nextage Stock performance.
| Return On Asset | -0.37 | |||
| Profit Margin | (2.30) % | |||
| Operating Margin | (9.71) % | |||
| Shares Outstanding | 2.27 M | |||
| Price To Earning | (91.98) X | |||
| Price To Book | 4.68 X | |||
| Price To Sales | 26.11 X | |||
| Revenue | 297 K | |||
| EBITDA | (5.38 M) | |||
| Cash And Equivalents | 358 K | |||
| Cash Per Share | 0.16 X | |||
| Debt To Equity | 65.70 % | |||
| Book Value Per Share | 0.90 X | |||
| Cash Flow From Operations | (5 M) | |||
| Earnings Per Share | (0.24) X | |||
| Total Asset | 6.01 M | |||
| Retained Earnings | (103 M) | |||
| Current Asset | 3 M | |||
| Current Liabilities | 2 M | |||
About Nextage Therapeutics Performance
By analyzing Nextage Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Nextage Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nextage Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nextage Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.Things to note about Nextage Therapeutics performance evaluation
Checking the ongoing alerts about Nextage Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nextage Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nextage Therapeutics had very high historical volatility over the last 90 days | |
| The company has 0.0 in debt which may indicate that it relies heavily on debt financing | |
| The company has a current ratio of 0.43, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Nextage Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Nextage Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nextage Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nextage to invest in growth at high rates of return. When we think about Nextage Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Nextage Therapeutics reported the revenue of 297 K. Net Loss for the year was (2.09 M) with profit before overhead, payroll, taxes, and interest of 207 K. | |
| Nextage Therapeutics has accumulated about 358 K in cash with (5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Nextage Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nextage Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Nextage Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nextage Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nextage Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nextage Therapeutics' stock. These opinions can provide insight into Nextage Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nextage Stock analysis
When running Nextage Therapeutics' price analysis, check to measure Nextage Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nextage Therapeutics is operating at the current time. Most of Nextage Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nextage Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nextage Therapeutics' price. Additionally, you may evaluate how the addition of Nextage Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |